Evidence map›Paper›PMID 41465420›Full record

ArticleInternational journal of molecular sciences2025

Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence.

Percy S Agogo-Mawuli, Joshua D Gross, Vincent Setola, Bryan J Gall, David P Siderovski

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Percy S Agogo-MawuliDepartment of Pharmacology and Neuroscience, College of Biomedical & Translational Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0001-6563-3376
Joshua D GrossDepartments of Nutritional Sciences and Biobehavioral Health, Huck Life Sciences Institute, Pennsylvania State University, University Park, PA 27710, USA.ORCID 0000-0002-0925-6331
Vincent SetolaDepartment of Behavioral Medicine & Psychiatry, WVU School of Medicine, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA.ORCID 0000-0002-9791-2270
Bryan J GallVariant Science Team, NeoGenomics, Fort Myers, FL 33912, USA.ORCID 0000-0002-2284-8892
David P SiderovskiDepartment of Pharmacology and Neuroscience, College of Biomedical & Translational Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-0688-8210

Funding

The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptorR01DA048153 · NIDA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SIDEROVSKI, DAVID P. · 2021 to 2025
$1.8M
NIDA NIH HHS R01 DA048153NIDA NIH HHS R01DA048153
6 · The paper itself

Abstract

Our goal in this study was to determine whether functional variation in the human

Indexed as

AffectBipolar DisorderCentral Nervous System StimulantsMethylphenidateRGS ProteinsAnimalsAttention Deficit Disorder with HyperactivityHumansMaleMethamphetamineMiceMice, KnockoutCentral Nervous System StimulantsMethamphetamineMethylphenidateRGS Proteinsattention-deficit/hyperactivity disorderbipolar disordermethylphenidatepsychostimulant-induced locomotionregulator of G protein signaling-12 (RGS12)

Identifiers

PMID41465420
PMCPMC12733212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.